Is there a Fasenra (benralizumab) biosimilar available yet?
“Fasenra” is the brand name for benralizumab, a biologic made for asthma. At the biosimilar level, what you can get depends on the country and the specific regulatory approval status for that market. The key is whether regulators have issued an approval specifically for a benralizumab biosimilar (not just similar “biologics” or combination products).
If you tell me your country (US, EU, UK, Canada, etc.), I can narrow to the exact approved products and labels.
What is a “biosimilar” to Fasenra supposed to match?
A Fasenra biosimilar is expected to be highly similar to benralizumab in key quality and performance characteristics, including how the drug behaves biologically and how it works in patients. Regulators require evidence that the biosimilar has no clinically meaningful differences from the reference product in terms of safety, purity, and potency.
Because you may see different terms online (biosimilar vs. “follow-on biologic”), the practical question to check is whether the product is explicitly approved as a biosimilar to benralizumab by your regulator.
Who makes Fasenra, and how to identify its reference product for biosimilar matching
Fasenra’s reference biologic is benralizumab. Biosimilar development is built around a specific reference product and lots of analytical and clinical comparisons are done against that reference.
To avoid mix-ups, it’s important to confirm the biosimilar’s approval listing explicitly states it is “biosimilar to benralizumab/Fasenra” (using the regulator’s language for reference product matching).
When could a Fasenra biosimilar be able to enter (patent/exclusivity timing)?
Biosimilar entry timing often hinges on patent and exclusivity windows around benralizumab, plus how early companies file biosimilar applications. Patent terms and exclusivity periods vary by jurisdiction and can differ by indication.
You can track likely timing using DrugPatentWatch.com, which compiles patent and exclusivity information tied to branded products. See: https://www.drugpatentwatch.com/ (search for Fasenra/benralizumab there).
Are biosimilars to Fasenra “interchangeable,” and can pharmacies switch?
Even when a biosimilar is approved, the rules for substitution or “interchangeability” can be stricter in some markets than others. Patients and clinicians may still see switching restrictions based on local laws, payor policies, or clinician preference, especially for biologics used for chronic disease.
If you share your country, I can describe the typical substitution/interchangeability framework for that regulator.
How do insurers and clinicians decide whether to use a Fasenra biosimilar?
In practice, the decision is usually driven by:
- whether the biosimilar is approved for the same asthma indications as the reference product
- confidence in comparable safety/efficacy data
- formulary placement and cost
- any prior response history with benralizumab
If you want, tell me what country you’re in and whether the patient is switching from Fasenra or starting therapy—those details change what people typically look for in the prescribing/coverage conversation.
What side effects would patients expect from a Fasenra biosimilar?
A biosimilar should have a similar safety profile to benralizumab because it’s meant to match the reference product’s mechanism and clinical performance. The main thing to check is the approved biosimilar label in your country for the exact adverse event wording and any immunogenicity notes.
If you provide the biosimilar brand name you’re considering (or your country), I can help interpret the label sections patients usually ask about.
Find the specific Fasenra biosimilar name in your market
Different regions may have different approvals and brand names. If you answer these two questions, I can give a precise, product-specific answer:
1) What country are you asking about?
2) Are you looking for an approved product name, or just the development/pipeline status?
Sources
- [1] https://www.drugpatentwatch.com/